Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Immunome Inc (NASDAQ: IMNM) was $19.49 for the day, down -3.99% from the previous closing price of $20.3. In other words, the price has decreased by -$3.99 from its previous closing price. On the day, 1.12 million shares were traded. IMNM stock price reached its highest trading level at $20.8 during the session, while it also had its lowest trading level at $19.265.
Ratios:
Our analysis of IMNM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.90 and its Current Ratio is at 8.90. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on December 01, 2025, initiated with a Buy rating and assigned the stock a target price of $36. On September 22, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $26. On September 05, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $26.Craig Hallum initiated its Buy rating on September 05, 2025, with a $26 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 03 ’25 when BIENAIME JEAN JACQUES bought 5,000 shares for $9.38 per share. The transaction valued at 46,900 led to the insider holds 36,415 shares of the business.
BIENAIME JEAN JACQUES bought 7,800 shares of IMNM for $60,684 on Mar 25 ’25. The Director now owns 31,415 shares after completing the transaction at $7.78 per share. On Mar 26 ’25, another insider, SIEGALL CLAY B, who serves as the President and CEO of the company, bought 137,100 shares for $7.29 each. As a result, the insider paid 999,459 and bolstered with 806,736 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMNM now has a Market Capitalization of 1787433344 and an Enterprise Value of 1518807296. For the stock, the TTM Price-to-Sale (P/S) ratio is 184.65 while its Price-to-Book (P/B) ratio in mrq is 6.77. Its current Enterprise Value per Revenue stands at 156.918 whereas that against EBITDA is -7.425.
Stock Price History:
The Beta on a monthly basis for IMNM is 2.24, which has changed by 0.5492846 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, IMNM has reached a high of $20.46, while it has fallen to a 52-week low of $5.15. The 50-Day Moving Average of the stock is 16.99%, while the 200-Day Moving Average is calculated to be 78.49%.
Shares Statistics:
IMNM traded an average of 1.50M shares per day over the past three months and 1046340 shares per day over the past ten days. A total of 91.71M shares are outstanding, with a floating share count of 89.10M. Insiders hold about 2.85% of the company’s shares, while institutions hold 96.17% stake in the company. Shares short for IMNM as of 1764288000 were 15269901 with a Short Ratio of 10.18, compared to 1761868800 on 15092876. Therefore, it implies a Short% of Shares Outstanding of 15269901 and a Short% of Float of 17.349999999999998.
Earnings Estimates
The dynamic stock of Immunome Inc (IMNM) is currently being evaluated by a team of 10.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.51 and low estimates of -$0.64.
Analysts are recommending an EPS of between -$1.9 and -$2.41 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$2.58, with 10.0 analysts recommending between -$1.93 and -$3.52.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for IMNM’s current fiscal year. The highest revenue estimate was $11M, while the lowest revenue estimate was $6.9M, resulting in an average revenue estimate of $7.78M. In the same quarter a year ago, actual revenue was $9.04M
